Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Neuro-Oncology
Erschienen in: Journal of Neuro-Oncology 3/2014

01.09.2014 | Topic Review

Neurosurgical oncology: advances in operative technologies and adjuncts

verfasst von: Randy S. D’Amico, Benjamin C. Kennedy, Jeffrey N. Bruce

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Modern glioma surgery has evolved around the central tenet of safely maximizing resection. Recent surgical adjuncts have focused on increasing the maximum extent of resection while minimizing risk to functional brain. Technologies such as cortical and subcortical stimulation mapping, intraoperative magnetic resonance imaging, functional neuronavigation, navigable intraoperative ultrasound, neuroendoscopy, and fluorescence-guided resection have been developed to augment the identification of tumor while preserving brain anatomy and function. However, whether these technologies offer additional long-term benefits to glioma patients remains to be determined. Here we review advances over the past decade in operative technologies that have offered the most promising benefits for glioblastoma patients.
Literatur
1.
Vuorinen V et al (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 145(1):5–10
2.
Stummer W et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401PubMed
3.
Stummer W et al (2012) Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108(1):89–97PubMedPubMedCentral
4.
Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52(4):371–379PubMed
5.
Lacroix M et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198PubMed
6.
Sanai N et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3–8PubMed
7.
Pope WB et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26(10):2466–2474PubMed
8.
Metcalfe SE (2000) Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev (2):CD002034
9.
Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4):753–764; discussion 264–266
10.
Duffau H et al (2003) Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patients. J Neurosurg 98(4):764–778PubMed
11.
Berger MS, Ojemann GA (1992) Intraoperative brain mapping techniques in neuro-oncology. Stereotact Funct Neurosurg 58(1–4):153–161PubMed
12.
Danks RA et al (2000) Craniotomy under local anesthesia and monitored conscious sedation for the resection of tumors involving eloquent cortex. J Neurooncol 49(2):131–139PubMed
13.
Grundy BL (1983) Intraoperative monitoring of sensory-evoked potentials. Anesthesiology 58(1):72–87PubMed
14.
Allen A, Starr A, Nudleman K (1981) Assessment of sensory function in the operating room utilizing cerebral evoked potentials: a study of fifty-six surgically anesthetized patients. Clin Neurosurg 28:457–481PubMed
15.
De Witt Hamer PC et al (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30(20):2559–2565PubMed
16.
Duffau H (2009) A personal consecutive series of surgically treated 51 cases of insular WHO Grade II glioma: advances and limitations. J Neurosurg 110(4):696–708PubMed
17.
Duffau H et al (2008) Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg 109(3):461–471PubMed
18.
Eisner W et al (2002) Use of neuronavigation and electrophysiology in surgery of subcortically located lesions in the sensorimotor strip. J Neurol Neurosurg Psychiatry 72(3):378–381PubMedPubMedCentral
19.
Keles GE et al (2004) Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. J Neurosurg 100(3):369–375PubMed
20.
Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358(1):18–27PubMed
21.
Sanai N (2012) Emerging operative strategies in neurosurgical oncology. Curr Opin Neurol 25(6):756–766PubMed
22.
Golfinos JG et al (1995) Clinical use of a frameless stereotactic arm: results of 325 cases. J Neurosurg 83(2):197–205PubMed
23.
Gumprecht HK, Widenka DC, Lumenta CB (1999) BrainLab VectorVision neuronavigation system: technology and clinical experiences in 131 cases. Neurosurgery 44(1):97–104; discussion 104–105
24.
Kurimoto M et al (2004) Impact of neuronavigation and image-guided extensive resection for adult patients with supratentorial malignant astrocytomas: a single-institution retrospective study. Minim Invasive Neurosurg 47(5):278–283PubMed
25.
Roberts DW et al (1986) A frameless stereotaxic integration of computerized tomographic imaging and the operating microscope. J Neurosurg 65(4):545–549PubMed
26.
Willems PW et al (2006) Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J Neurosurg 104(3):360–368PubMed
27.
Bizzi A et al (2008) Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology 248(2):579–589PubMed
28.
Krishnan R et al (2004) Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome. Neurosurgery 55(4):904–914; discusssion 914–915
29.
Wu JS et al (2007) Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery 61(5):935–948; discussion 948–949
30.
Gonzalez-Darder JM et al (2010) Multimodal navigation in the functional microsurgical resection of intrinsic brain tumors located in eloquent motor areas: role of tractography. Neurosurg Focus 28(2):E5PubMed
31.
Schulder M et al (1998) Functional image-guided surgery of intracranial tumors located in or near the sensorimotor cortex. J Neurosurg 89(3):412–418PubMed
32.
McDonald JD et al (1999) Integration of preoperative and intraoperative functional brain mapping in a frameless stereotactic environment for lesions near eloquent cortex. Technical note. J Neurosurg 90(3):591–598PubMed
33.
Coenen VA et al (2001) Three-dimensional visualization of the pyramidal tract in a neuronavigation system during brain tumor surgery: first experiences and technical note. Neurosurgery 49(1):86–92; discussion 92–93
34.
Kumar A et al (2014) The role of neuronavigation-guided functional MRI and diffusion tensor tractography along with cortical stimulation in patients with eloquent cortex lesions. Br J Neurosurg 28(2):226–233PubMed
35.
Schonberg T et al (2006) Characterization of displaced white matter by brain tumors using combined DTI and fMRI. Neuroimage 30(4):1100–1111PubMed
36.
Berntsen EM et al (2010) Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery 67(2):251–264PubMed
37.
Romano A et al (2009) Pre-surgical planning and MR-tractography utility in brain tumour resection. Eur Radiol 19(12):2798–2808PubMed
38.
Romano A et al (2007) Role of magnetic resonance tractography in the preoperative planning and intraoperative assessment of patients with intra-axial brain tumours. Radiol Med 112(6):906–920PubMed
39.
Yu CS et al (2005) Diffusion tensor tractography in patients with cerebral tumors: a helpful technique for neurosurgical planning and postoperative assessment. Eur J Radiol 56(2):197–204PubMed
40.
Bello L et al (2010) Intraoperative use of diffusion tensor imaging fiber tractography and subcortical mapping for resection of gliomas: technical considerations. Neurosurg Focus 28(2):E6PubMed
41.
Mikuni N et al (2007) Clinical impact of integrated functional neuronavigation and subcortical electrical stimulation to preserve motor function during resection of brain tumors. J Neurosurg 106(4):593–598PubMed
42.
Bello L et al (2008) Motor and language DTI Fiber Tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. Neuroimage 39(1):369–382PubMed
43.
De Nigris D, Collins DL, Arbel T (2013) Fast rigid registration of pre-operative magnetic resonance images to intra-operative ultrasound for neurosurgery based on high confidence gradient orientations. Int J Comput Assist Radiol Surg 8(4):649–661PubMed
44.
Black PM et al (1997) Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery 41(4):831–842; discussion 842–845
45.
Bohinski RJ et al (2001) Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery 49(5):1133–1143; discussion 1143–1144
46.
Claus EB et al (2005) Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103(6):1227–1233PubMed
47.
Gerlach R et al (2008) Feasibility of Polestar N20, an ultra-low-field intraoperative magnetic resonance imaging system in resection control of pituitary macroadenomas: lessons learned from the first 40 cases. Neurosurgery 63(2):272–284; discussion 284–285
48.
Nimsky C et al (2004) Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging. Neurosurgery 55(2):358–370; discussion 370–371
49.
Nimsky C et al (2006) Intraoperative high-field magnetic resonance imaging in transsphenoidal surgery of hormonally inactive pituitary macroadenomas. Neurosurgery 59(1):105–114; discussion 105–114
50.
Schwartz TH, Stieg PE, Anand VK (2006) Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging. Neurosurgery 58(1 Suppl):ONS44–ONS51; discussion ONS44–ONS51
51.
Schneider JP et al (2005) Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme—a quantitative radiological analysis. Neuroradiology 47(7):489–500PubMed
52.
Senft C et al (2011) Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12(11):997–1003PubMed
53.
Kuhnt D et al (2011) Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 13(12):1339–1348PubMedPubMedCentral
54.
Hatiboglu MA et al (2009) Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 64(6):1073–1081; discussion 1081
55.
Senft C et al (2008) Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 63(4 Suppl 2):257–266; discussion 266–267
56.
Nimsky C et al (2004) Intraoperative high-field-strength MR imaging: implementation and experience in 200 patients. Radiology 233(1):67–78PubMed
57.
Nimsky C et al (2003) Preliminary experience in glioma surgery with intraoperative high-field MRI. Acta Neurochir Suppl 88:21–29PubMed
58.
Schulder M, Carmel PW (2003) Intraoperative magnetic resonance imaging: impact on brain tumor surgery. Cancer Control 10(2):115–124PubMed
59.
Senft C et al (2010) Low field intraoperative MRI-guided surgery of gliomas: a single center experience. Clin Neurol Neurosurg 112(3):237–243PubMed
60.
Wirtz CR et al (2000) Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery 46(5):1112–1120; discussion 1120–1122
61.
Kubben PL et al (2011) Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 12(11):1062–1070PubMed
62.
Foroglou N, Zamani A, Black P (2009) Intra-operative MRI (iop-MR) for brain tumour surgery. Br J Neurosurg 23(1):14–22PubMed
63.
Hirschberg H et al (2005) Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg 48(2):77–84PubMed
64.
Hall WA, Truwit CL (2008) Intraoperative MR-guided neurosurgery. J Magn Reson Imaging 27(2):368–375PubMed
65.
Knauth M et al (1999) Surgically induced intracranial contrast enhancement: potential source of diagnostic error in intraoperative MR imaging. AJNR Am J Neuroradiol 20(8):1547–1553PubMed
66.
Ozduman K et al (2014) Using intraoperative dynamic contrast-enhanced T1-weighted MRI to identify residual tumor in glioblastoma surgery. J Neurosurg 120(1):60–66PubMed
67.
Moiyadi A, Shetty P (2011) Objective assessment of utility of intraoperative ultrasound in resection of central nervous system tumors: a cost-effective tool for intraoperative navigation in neurosurgery. J Neurosci Rural Pract 2(1):4–11PubMedPubMedCentral
68.
Unsgaard G et al (2002) Brain operations guided by real-time two-dimensional ultrasound: new possibilities as a result of improved image quality. Neurosurgery 51(2):402–411; discussion 411–412
69.
Dohrmann GJ, Rubin JM (2001) History of intraoperative ultrasound in neurosurgery. Neurosurg Clin N Am 12(1):155–166, ix
70.
Moiyadi AV et al (2013) Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien) 155(12):2217–2225
71.
Solheim O et al (2010) Ultrasound-guided operations in unselected high-grade gliomas—overall results, impact of image quality and patient selection. Acta Neurochir (Wien) 152(11):1873–1886
72.
Unsgaard G et al (2005) Ability of navigated 3D ultrasound to delineate gliomas and metastases—comparison of image interpretations with histopathology. Acta Neurochir (Wien) 147(12):1259–1269; discussion 1269
73.
Bonsanto MM et al (2005) 3D ultrasound navigation in syrinx surgery—a feasibility study. Acta Neurochir (Wien) 147(5):533–540; discussion 540–541
74.
Kolstad F et al (2006) Three-dimensional ultrasonography navigation in spinal cord tumor surgery. Technical note. J Neurosurg Spine 5(3):264–270PubMed
75.
Glasker S et al (2011) Doppler-sonographically guided resection of central nervous system hemangioblastomas. Neurosurgery 68(2 Suppl Operative):267–275; discussion 274–275
76.
Jakola AS et al (2012) The influence of surgery on quality of life in patients with intracranial meningiomas: a prospective study. J Neurooncol 110(1):137–144PubMed
77.
Engelhardt M et al (2007) Feasibility of contrast-enhanced sonography during resection of cerebral tumours: initial results of a prospective study. Ultrasound Med Biol 33(4):571–575PubMed
78.
He W et al (2008) Intraoperative contrast-enhanced ultrasound for brain tumors. Clin Imaging 32(6):419–424PubMed
79.
Saether CA et al (2012) Did survival improve after the implementation of intraoperative neuronavigation and 3D ultrasound in glioblastoma surgery? A retrospective analysis of 192 primary operations. J Neurol Surg A Cent Eur Neurosurg 73(2):73–78PubMed
80.
Unsgaard G et al (2006) Intra-operative 3D ultrasound in neurosurgery. Acta Neurochir (Wien) 148(3):235–253; discussion 253
81.
Rohde V, Coenen VA (2011) Intraoperative 3-dimensional ultrasound for resection control during brain tumour removal: preliminary results of a prospective randomized study. Acta Neurochir Suppl 109:187–190PubMed
82.
Roth J et al (2007) Real-time neuronavigation with high-quality 3D ultrasound SonoWand in pediatric neurosurgery. Pediatr Neurosurg 43(3):185–191PubMed
83.
Steno A et al (2012) Navigated three-dimensional intraoperative ultrasound-guided awake resection of low-grade glioma partially infiltrating optic radiation. Acta Neurochir (Wien) 154(7):1255–1262
84.
Diez Valle R et al (2011) Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 102(1):105–113PubMed
85.
Rygh OM et al (2008) Comparison of navigated 3D ultrasound findings with histopathology in subsequent phases of glioblastoma resection. Acta Neurochir (Wien) 150(10):1033–1041; discussion 1042
86.
Selbekk T et al (2013) Ultrasound imaging in neurosurgery: approaches to minimize surgically induced image artefacts for improved resection control. Acta Neurochir (Wien) 155(6):973–980
87.
Coenen VA et al (2005) Sequential visualization of brain and fiber tract deformation during intracranial surgery with three-dimensional ultrasound: an approach to evaluate the effect of brain shift. Neurosurgery 56(1 Suppl):133–141; discussion 133–141
88.
Albert FK et al (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34(1):45–60; discussion 60–61
89.
Berger MS (1994) Malignant astrocytomas: surgical aspects. Semin Oncol 21(2):172–185PubMed
90.
Ritz R et al (2012) Hypericin for visualization of high grade gliomas: first clinical experience. Eur J Surg Oncol 38(4):352–360PubMed
91.
Valdes PA et al (2011) Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 115(1):11–17PubMedPubMedCentral
92.
Della Puppa A et al (2013) 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. Acta Neurochir (Wien) 155(6):965–972; discussion 972
93.
Schucht P et al (2012) Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 71(5):927–935; discussion 935–936
94.
Sanai N et al (2011) Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg 115(4):740–748PubMed
95.
Sanai N et al (2011) Intraoperative confocal microscopy for brain tumors: a feasibility analysis in humans. Neurosurgery 68(2 Suppl Operative):282–290; discussion 290
96.
Schucht P et al (2014) 5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma. Acta Neurochir (Wien) 156(2):305–312; discussion 312
97.
Aldave G et al (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery. Neurosurgery 72(6):915–920; discussion 920–921
98.
Roessler K et al (2012) Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery. Neurol Res 34(3):314–317PubMed
99.
Li Y et al (2013) Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies. World Neurosurg. doi:10.​1016/​j.​wneu.​2013.​06.​014
100.
Roberts DW et al (2011) Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 114(3):595–603PubMedPubMedCentral
101.
Miyatake S et al (2007) Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report. Neurosurgery 61(5):E1101–E1103; discussion E1103–E1104
102.
Grossman R et al (2014) Intraoperative 5-aminolevulinic acid-induced fluorescence in primary central nervous system lymphoma. J Neurosurg 120(1):67–69PubMed
103.
Hefti M et al (2008) 5-Aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly 138(11–12):180–185PubMed
104.
Stummer W et al (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42(3):518–525; discussion 525–526
105.
Stummer W et al (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93(6):1003–1013PubMed
106.
Shinoda J et al (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99(3):597–603PubMed
107.
Koc K et al (2008) Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 22(1):99–103PubMed
108.
Acerbi F et al (2014) Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus 36(2):E5PubMed
109.
Cappabianca P et al (2002) Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg 97(2):293–298PubMed
110.
Cappabianca P, Cavallo LM, de Divitiis E (2004) Endoscopic endonasal transsphenoidal surgery. Neurosurgery 55(4):933–940; discussion 940–941
111.
Jho HD et al (1997) Endoscopic pituitary surgery: an early experience. Surg Neurol 47(3):213–222; discussion 222–223
112.
Frank G et al (2006) The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology 83(3–4):240–248PubMed
113.
Laufer I, Anand VK, Schwartz TH (2007) Endoscopic, endonasal extended transsphenoidal, transplanum transtuberculum approach for resection of suprasellar lesions. J Neurosurg 106(3):400–406PubMed
114.
115.
Powell M (2009) Microscope and endoscopic pituitary surgery. Acta Neurochir (Wien) 151(7):723–728
116.
Morgenstern PF, Souweidane MM (2013) Pineal region tumors: simultaneous endoscopic third ventriculostomy and tumor biopsy. World Neurosurg 79(2 Suppl):S18-e9–S18-e13
117.
Al-Tamimi YZ et al (2008) Endoscopic biopsy during third ventriculostomy in paediatric pineal region tumours. Childs Nerv Syst 24(11):1323–1326PubMed
118.
O’Brien DF et al (2006) Outcomes in patients undergoing single-trajectory endoscopic third ventriculostomy and endoscopic biopsy for midline tumors presenting with obstructive hydrocephalus. J Neurosurg 105(3 Suppl):219–226PubMed
119.
Yamini B et al (2004) Initial endoscopic management of pineal region tumors and associated hydrocephalus: clinical series and literature review. J Neurosurg 100(5 Suppl Pediatrics):437–441PubMed
120.
Rohde V et al (2012) The role of neuronavigation in intracranial endoscopic procedures. Neurosurg Rev 35(3):351–358PubMedPubMedCentral
121.
Pople IK et al (2001) The role of endoscopic biopsy and third ventriculostomy in the management of pineal region tumours. Br J Neurosurg 15(4):305–311PubMed
122.
Robinson S, Cohen AR (1997) The role of neuroendoscopy in the treatment of pineal region tumors. Surg Neurol 48(4):360–365; discussion 365–367
123.
Kim IY et al (2004) Neuronavigation-guided endoscopic surgery for pineal tumors with hydrocephalus. Minim Invasive Neurosurg 47(6):365–368PubMed
124.
Schroeder HW et al (2001) Frameless neuronavigation in intracranial endoscopic neurosurgery. J Neurosurg 94(1):72–79PubMed
125.
Chernov MF et al (2006) Neurofiberscopic biopsy of tumors of the pineal region and posterior third ventricle: indications, technique, complications, and results. Neurosurgery 59(2):267–277; discussion 267–277
126.
Gangemi M et al (2001) Endoscopic surgery for pineal region tumors. Minim Invasive Neurosurg 44(2):70–73PubMed
127.
Barkhoudarian G, Romero ADCB, Laws ER (2013) Evaluation of the 3-dimensional endoscope in transsphenoidal surgery. Neurosurgery 73(1 Suppl Operative):ons74–ons78; discussion ons78–ons79
128.
Tabaee A et al (2009) Three-dimensional endoscopic pituitary surgery. Neurosurgery 64(5 Suppl 2):288–293; discussion 294–295
129.
Kari E et al (2012) Comparison of traditional 2-dimensional endoscopic pituitary surgery with new 3-dimensional endoscopic technology: intraoperative and early postoperative factors. Int Forum Allergy Rhinol 2(1):2–8PubMed
130.
Brem H et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345(8956):1008–1012PubMed
131.
Westphal M et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5(2):79–88PubMedPubMedCentral
132.
Attenello FJ et al (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15(10):2887–2893PubMed
133.
Westphal M et al (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148(3):269–275; discussion 275
134.
Valtonen S et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1):44–48; discussion 48–49
135.
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMed
136.
Bock HC et al (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33(4):441–449PubMedPubMedCentral
137.
McGirt MJ et al (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583–588PubMed
138.
Menei P et al (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17(7):1740–1746PubMed
139.
Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88(3):353–357PubMed
140.
Affronti ML et al (2009) Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115(15):3501–3511PubMed
141.
Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53(3):220–224PubMed
142.
McGirt MJ et al (2002) Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg 96(5):941–945PubMed
143.
Subach BR et al (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45(1):17–22; discussion 22–23
144.
Weber EL, Goebel EA (2005) Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 7(1):84–89PubMedPubMedCentral
145.
Bregy A et al (2013) The role of Gliadel wafers in the treatment of high-grade gliomas. Expert Rev Anticancer Ther 13(12):1453–1461PubMed
146.
Bobo RH et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91(6):2076–2080PubMedPubMedCentral
147.
Juratli TA, Schackert G, Krex D (2013) Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther 139(3):341–358PubMed
148.
Bruce JN et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69(6):1272–1279; discussion 1279–1280
149.
Lidar Z et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100(3):472–479PubMed
150.
Bogdahn U et al (2011) Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13(1):132–142PubMedPubMedCentral
151.
Carpentier A et al (2010) Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12(4):401–408PubMedPubMedCentral
152.
Sampson JH et al (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10(3):320–329PubMedPubMedCentral
153.
Weber FW et al (2003) Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:93–103PubMed
154.
Sampson JH et al (2003) Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65(1):27–35PubMed
155.
Kunwar S et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12(8):871–881PubMedPubMedCentral
156.
Sampson JH et al (2010) Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113(2):301–309PubMed
157.
Mueller S et al (2011) Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 101(2):267–277PubMedPubMedCentral
158.
Anderson RC et al (2013) Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr 11(3):289–295PubMed
159.
Kunwar S et al (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20(4):E15PubMed
160.
Parney IF et al (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102(2):267–275PubMed
161.
Vogelbaum MA et al (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61(5):1031–1037; discussion 1037–1038
162.
Sampson JH et al (2007) Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60(2 Suppl 1): ONS89–ONS98; discussion ONS98–ONS99
163.
Chen MY et al (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90(2):315–320PubMed
164.
Saito R et al (2011) Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr 7(5):522–526PubMed
165.
Sampson JH et al (2011) Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery 69(3):668–676PubMedPubMedCentral
166.
Lonser RR et al (2007) Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 107(1):190–197PubMed
167.
Chittiboina P et al (2014) Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr 13(3):276–282PubMed
Metadaten
Titel
Neurosurgical oncology: advances in operative technologies and adjuncts
verfasst von
Randy S. D’Amico
Benjamin C. Kennedy
Jeffrey N. Bruce
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1493-3

Weitere Artikel der Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014 Zur Ausgabe

Perspective

A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium

Topic Review

Stem cells and gliomas: past, present, and future

Topic Review

Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective

Topic Review

Vaccine therapies for patients with glioblastoma

Topic Review

The evolving role of neurological imaging in neuro-oncology

Topic Review

Medical therapy of gliomas

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise